TabletsTablets
Schedule H (Prescription Required)Antihypertensives & BP RegulatorsCode: 2393

Azelnidipine 8mg + Telmisartan 40mg Tablets

Generic Formulation:Azelnidipine 8mg + Telmisartan 40mg Tablets
Pack Size:10's
Common Commercial Brand Equivalents:Market reference only
Jan Aushadhi MRP
₹42.19
Brand Estimate*
₹176.84
Estimated Savings:₹134.65 (76% saved)
Find a Kendra Near You
*Statutory price across 21,118 listed Kendras
Clinical InformationReport Error

Clinical Overview

Telmisartan is a potent, non-peptide, long-acting angiotensin II type 1 (AT1) receptor antagonist on the WHO Model List of Essential Medicines. It exhibits an exceptionally long elimination half-life (around 24 hours) providing sustained 24-hour blood pressure control with high trough-to-peak ratio, and uniquely functions as a partial agonist at peroxisome proliferator-activated receptor-gamma (PPAR-gamma), improving glucose handling and lipid metabolism. Indicated for essential hypertension and cardiovascular risk reduction in patients with coronary artery disease, stroke, or diabetes with end-organ damage.

AI-assistedClinical summary synthesized from pharmacopoeial references (CDSCO, WHO EML, IP/BP/USP). Not clinician-reviewed. Drug code 2393.Report inaccuracy

Usage Guidelines

Take orally once daily with water, with or without food, at the same time each day. Full antihypertensive effect is generally evident within 4 to 8 weeks of starting therapy. Do not stop without consulting your doctor.

General Administration Advice: Adhere strictly to the prescribed dosage, frequency, and treatment course. For oral medications, swallow with sufficient water. Never stop antibiotics, psychiatric medications, or antihypertensives abruptly without clinical direction.

Possible Side Effects

Common: Upper respiratory tract symptoms, dizziness, back pain, sinus congestion, diarrhea, pharyngitis. Rare/Severe: Boxed warning: Fetal toxicity; acute renal failure, hyperkalemia, angioedema, and symptomatic hypotension in salt/volume-depleted patients.

*Note: Individual physiological responses vary. While many patients experience few or no side effects, notify your treating physician if adverse reactions persist or if hypersensitivity (angioedema, skin rash, dyspnea) occurs.

Precautions & Warnings

Black box warning: Discontinue immediately if pregnancy occurs; ARBs acting on the renin-angiotensin system cause oligohydramnios, fetal cranial hypoplasia, and intrauterine death. Caution in bilateral renal artery stenosis. Avoid potassium supplements or salt substitutes without medical advice.

Schedule H (Prescription Required)

This medication is scheduled under statutory drug regulatory frameworks (CDSCO / Drugs & Cosmetics Rules). Dispensing requires a valid medical prescription from a registered medical practitioner. Self-medication or unsupervised dosage adjustment carries significant clinical risks.

Medical Disclaimer: Statutory Clinical Disclaimer: The information provided is for educational and price-transparency purposes only and does not constitute medical advice, clinical diagnosis, or treatment recommendations. Always consult a registered medical practitioner or qualified cardiologist/pharmacist before initiating, altering, or substituting any cardiovascular medication.